Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Managing progression after BCMA-targeted therapy in R/R multiple myeloma

Carlos Fernández De Larrea • 10 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Belantamab mafodotin CAR-T

Carlos Fernandez de Larrea, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the challenges associated with relapse after BCMA-targeted therapy with CAR-Ts, antibody-drug conjugates (ADCs) or bispecific antibodies, highlighting the potential of targeting other antigens in patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Carlos Fernández De Larrea

Novel therapeutic strategies in multiple myeloma
Carlos Fernández De Larrea et al. • 15 Apr 2023
5:35
Safety & efficacy of ARI0002H in R/R multiple myeloma
Carlos Fernández De Larrea • 11 Jun 2022
1:02
CD229 as a potential therapeutic target for multiple myeloma
Carlos Fernández De Larrea • 10 Jun 2022
1:22
Safety and efficacy of ARI0002h for R/R MM
Carlos Fernández De Larrea • 10 Jun 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals